Celcuity Inc. (CELC)

17,67 +0,01 (+0,06%) Börsenschluss: 04:00PM EDT

Celcuity Inc.

16305–36th Avenue North
Suite 100
Minneapolis, MN 55446
United States
763 392 0767
https://www.celcuity.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 55

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Brian F. Sullivan	Co-Founder, Chairman & CEO	478,12k	N/A	1962
Dr. Lance G. Laing Ph.D.	Co-Founder, Chief Science Officer, VP, Secretary & Director	389,55k	N/A	1962
Ms. Vicky Hahne	Chief Financial Officer	281,59k	N/A	1966
Dr. John R. MacDonald Dabt, Ph., Ph.D.	Senior Vice President of R&D	N/A	N/A	1955
Ms. Sheri Smith	Acting Head of Clinical Operations	N/A	N/A	N/A
Mr. Igor Gorbatchevsky M.D.	Chief Medical Officer	N/A	N/A	N/A
Mr. Eldon C. Mayer III, M.B.A.	Chief Commercial Officer	N/A	N/A	1961

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.

Corporate Governance

Celcuity Inc.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 8. Die grundlegenden Scores sind Audit: 7, Vorstand: 9, Shareholderrechte: 6, Kompensation: 8.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.